Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX) is scheduled to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Catalyst Pharmaceuticals has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The company had revenue of $110.57 million during the quarter, compared to analysts’ expectations of $105.78 million. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Stock Down 2.0 %

CPRX stock opened at $14.72 on Monday. Catalyst Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $17.76. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 0.81 and a beta of 0.89. The business’s fifty day simple moving average is $15.65 and its two-hundred day simple moving average is $14.71.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the transaction, the insider now directly owns 124,433 shares in the company, valued at $2,045,678.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 21st. Citigroup began coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 target price for the company. Finally, Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $26.43.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.